Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 30, 2020
Reporting Period: Event date January 30, 2020
Context: The Company announced a fully backstopped rights offering to raise capital and entered into a definitive investment agreement with affiliates of BVF Partners L.P.
Key Financial Metrics
Capital Raise Target: $30,000,000
Offering Price: $9.00 per share of Common Stock
Backstop Commitment: Up to $30,000,000 for nonvoting Series C convertible preferred stock
Preferred Stock Price: $9,000 per share (convertible into 1,000 shares of Common Stock)
Transaction Fees: No fee paid to BVF; Company to reimburse up to $50,000 of BVF expenses.
Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics.
Material Changes
- Entry into Material Definitive Agreement: Execution of an Investment Agreement with BVF Partners L.P. affiliates to backstop the rights offering.
- Unregistered Sales of Equity Securities: Agreement to issue Series C convertible preferred stock to BVF for any unsubscribed shares in the rights offering.
- Ownership Structure: As of September 30, 2019, BVF owned approximately 5% of outstanding Common Stock (approximately 17% on an as-converted basis including Series A and B).
Guidance, Outlook, and Risks
Outlook: The Company intends to raise $30 million to support its operations, though specific strategic use of proceeds is not detailed in this excerpt.
Terms of Series C Preferred Stock:
- Conversion: Convertible at holder's option into 1,000 shares of Common Stock per preferred share.
- Conversion Blocker: Conversion is prohibited if the holder would beneficially own more than 9.99% of total Common Stock immediately following conversion.
- Liquidation Preference: Pari passu with Common Stock, Series A, and Series B on an as-converted basis.
- Dividends: Entitled to dividends equal to those paid on Common Stock on an as-if-converted basis.
- Voting Rights: Generally no voting rights, except as required by law or to amend Series C terms.
Investor Verification Checklist
- Verify the final subscription amount and whether the full $30 million backstop was utilized.
- Review the full Investment Agreement (Exhibit 10.1) for detailed covenants and representations.
- Confirm the exact number of Series C Preferred shares issued to BVF upon closing.
- Check subsequent filings for the impact of the offering on total share count and dilution.
- Review the press release (Exhibit 99.1) for specific details on the use of proceeds.